The price of Immunogen, Inc. (NASDAQ:IMGN) shares last traded on Wall Street rose 3.34% to $16.11.
Based on available information, 16 analysts follow Immunogen, Inc. (NASDAQ:IMGN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $28.00 and a low of $14.00, we find $24.50. Given the previous closing price of $15.59, this indicates a potential upside of 57.15 percent. IMGN stock price is now 6.81% away from the 50-day moving average and 31.24% away from the 200-day moving average. The market capitalization of the company currently stands at $4.29B.
Among analysts, 2 rate the stock a hold while 13 rate it a buy. Brokers who have rated the stock have averaged $23.14 as their price target over the next twelve months.
With the price target of $25, Deutsche Bank recently initiated with Buy rating for Immunogen, Inc. (NASDAQ: IMGN).
In other news, Coen Stacy Ann, SVP & CHIEF BUSINESS OFFICER sold 78,223 shares of the company’s stock on Nov 17. The stock was sold for $1,255,479 at an average price of $16.05. Upon completion of the transaction, the SVP & CHIEF BUSINESS OFFICER now directly owns 36,966 shares in the company, valued at $0.6 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 16, SVP & CHIEF BUSINESS OFFICER Coen Stacy Ann sold 4,100 shares of the business’s stock. A total of $65,641 was realized by selling the stock at an average price of $16.01. This leaves the insider owning 36,966 shares of the company worth $0.6 million. Insiders disposed of 3,562,635 shares of company stock worth roughly $57.39 million over the past 1 year. A total of 2.57% of the company’s stock is owned by insiders.
A candlestick chart of Immunogen, Inc. (NASDAQ: IMGN) showed a price of $15.71 on Friday morning. During the past 12 months, Immunogen, Inc. has had a low of $3.61 and a high of $20.69. As of last week, the company has a debt-to-equity ratio of 0.20, a current ratio of 5.70, and a quick ratio of 5.65. The fifty day moving average price for IMGN is $15.09 and a two-hundred day moving average price translates $12.33 for the stock.
The latest earnings results from Immunogen, Inc. (NASDAQ: IMGN) was released for Sep, 2023. The net profit margin was -25.56% and return on equity was -19.88% for IMGN. The company reported revenue of $113.42 million for the quarter, compared to $15.38 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 637.72 percent.
Immunogen, Inc.(IMGN) Company Profile
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
